MELBOURNE, Australia, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (IMCIMRN, a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform for prevention and treatment of gut-mediated diseases; invites investors to join a live webcast hosted by Steven Lydeamore, CEO of Immuron Limited.
| Wednesday, 7 September 2022 at 9.00am Australian Eastern Standard Time (AEST). Register in advance for this webinar: https://us02web.zoom.us/webinar/register/WN_sCS7O27uRxWQPC3Z6ILa8g After registering, you will receive a confirmation email containing information about joining the webinar. |
This release has been authorised by the directors of Immuron Limited.
| COMPANY CONTACT: Steven Lydeamore Chief Executive Officer Ph: +61 (0)3 9824 5254 info@immuron.com |
About Immuron
Immuron Limited (IMCIMRN is a commercial and clinical-stage Australian biopharmaceutical company with a proprietary technology platform focused on a novel class of orally delivered polyclonal antibodies produced from hyperimmune antibody-rich bovine colostrum, for prevention and treatment of gut-mediated diseases.
For more information visit: http://www.immuron.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
